Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

T cell immunoglobulin-3 as a new therapeutic target for rheumatoid arthritis.

Li X, Zhao YQ, Li CW, Yuan FL.

Expert Opin Ther Targets. 2012 Dec;16(12):1145-9. doi: 10.1517/14728222.2012.726616. Epub 2012 Sep 22. Review.

PMID:
22998573
2.

TIM-3 as a new therapeutic target in systemic lupus erythematosus.

Pan HF, Zhang N, Li WX, Tao JH, Ye DQ.

Mol Biol Rep. 2010 Jan;37(1):395-8. doi: 10.1007/s11033-009-9833-7. Review.

PMID:
19768575
3.

Emerging Tim-3 functions in antimicrobial and tumor immunity.

Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK.

Trends Immunol. 2011 Aug;32(8):345-9. doi: 10.1016/j.it.2011.05.003. Epub 2011 Jun 21. Review.

4.

TIM-3 in autoimmunity.

Anderson AC, Anderson DE.

Curr Opin Immunol. 2006 Dec;18(6):665-9. Epub 2006 Oct 2. Review.

PMID:
17011764
5.

The role of T cell immunoglobulin and mucin domain-3 in immune thrombocytopenia.

Zhang XM, Shan NN.

Scand J Immunol. 2014 Apr;79(4):231-6. doi: 10.1111/sji.12153. Review.

6.

Expression of human TIM-3 and its correlation with disease activity in rheumatoid arthritis.

Lee J, Oh JM, Hwang JW, Ahn JK, Bae EK, Won J, Koh EM, Cha HS.

Scand J Rheumatol. 2011;40(5):334-40. doi: 10.3109/03009742.2010.547871. Epub 2011 Mar 30.

PMID:
21446887
7.

Underexpression of TIM-3 and blunted galectin-9-induced apoptosis of CD4+ T cells in rheumatoid arthritis.

Lee J, Park EJ, Noh JW, Hwang JW, Bae EK, Ahn JK, Koh EM, Cha HS.

Inflammation. 2012 Apr;35(2):633-7. doi: 10.1007/s10753-011-9355-z.

PMID:
21717191
8.

Novel insights into Tim-4 function in autoimmune diseases.

Fang XY, Xu WD, Pan HF, Leng RX, Ye DQ.

Autoimmunity. 2015 Jun;48(4):189-95. doi: 10.3109/08916934.2014.983266. Epub 2014 Nov 19. Review.

PMID:
25470136
9.

The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis.

Ju Y, Shang X, Liu Z, Zhang J, Li Y, Shen Y, Liu Y, Liu C, Liu B, Xu L, Wang Y, Zhang B, Zou J.

Mol Immunol. 2014 Mar;58(1):85-91. doi: 10.1016/j.molimm.2013.11.001. Epub 2013 Dec 10.

PMID:
24333756
10.

Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy: TIM-3/galectin-9 interaction and its possible role during pregnancy.

Meggyes M, Miko E, Polgar B, Bogar B, Farkas B, Illes Z, Szereday L.

PLoS One. 2014 Mar 20;9(3):e92371. doi: 10.1371/journal.pone.0092371. eCollection 2014.

11.

TIM-3 and its regulatory role in immune responses.

Zhu C, Anderson AC, Kuchroo VK.

Curr Top Microbiol Immunol. 2011;350:1-15. doi: 10.1007/82_2010_84. Review.

PMID:
20700701
12.

Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung.

Vega-Carrascal I, Bergin DA, McElvaney OJ, McCarthy C, Banville N, Pohl K, Hirashima M, Kuchroo VK, Reeves EP, McElvaney NG.

J Immunol. 2014 Mar 1;192(5):2418-31. doi: 10.4049/jimmunol.1300711. Epub 2014 Jan 29.

13.

The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis.

Chae SC, Park YR, Shim SC, Yoon KS, Chung HT.

Immunol Lett. 2004 Aug 15;95(1):91-5.

PMID:
15325803
14.

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.

Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, Zou W.

Hepatology. 2012 Oct;56(4):1342-51. doi: 10.1002/hep.25777.

15.

Involvement of Galectin-9/TIM-3 pathway in the systemic inflammatory response in early-onset preeclampsia.

Miko E, Meggyes M, Bogar B, Schmitz N, Barakonyi A, Varnagy A, Farkas B, Tamas P, Bodis J, Szekeres-Bartho J, Illes Z, Szereday L.

PLoS One. 2013 Aug 2;8(8):e71811. doi: 10.1371/journal.pone.0071811. Print 2013.

16.

Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells.

Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M, Nishi N, Yamauchi A, Quintana FJ, Sobel RA, Hirashima M, Kuchroo VK.

J Immunol. 2010 Aug 1;185(3):1383-92. doi: 10.4049/jimmunol.0903275. Epub 2010 Jun 23.

17.

Upregulation of the Tim-3/Gal-9 pathway and correlation with the development of preeclampsia.

Hao H, He M, Li J, Zhou Y, Dang J, Li F, Yang M, Deng D.

Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:85-91. doi: 10.1016/j.ejogrb.2015.08.022. Epub 2015 Aug 24.

PMID:
26342682
18.

Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes.

Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Eguchi J, Akiba H, Yagita H, Makino H.

Endocrinology. 2012 Feb;153(2):612-20. doi: 10.1210/en.2011-1579. Epub 2011 Dec 20.

PMID:
22186414
19.

Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection.

Elahi S, Niki T, Hirashima M, Horton H.

Blood. 2012 May 3;119(18):4192-204. doi: 10.1182/blood-2011-11-389585. Epub 2012 Mar 21.

20.

Tim-2 regulates T helper type 2 responses and autoimmunity.

Chakravarti S, Sabatos CA, Xiao S, Illes Z, Cha EK, Sobel RA, Zheng XX, Strom TB, Kuchroo VK.

J Exp Med. 2005 Aug 1;202(3):437-44. Epub 2005 Jul 25. Erratum in: J Exp Med. 2005 Sep 19;202(6):877.

Supplemental Content

Support Center